Business Description
Mayne Pharma Group Ltd
NAICS : 325412
SIC : 2834
ISIN : AU000000MYX0
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.85 | |||||
Equity-to-Asset | 0.4 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.45 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.77 | |||||
Beneish M-Score | -2.51 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.5 | |||||
3-Year EBITDA Growth Rate | 19.3 | |||||
3-Year EPS without NRI Growth Rate | -107.5 | |||||
3-Year Book Growth Rate | -13.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 12.45 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 46.26 | |||||
9-Day RSI | 48.28 | |||||
14-Day RSI | 50.17 | |||||
6-1 Month Momentum % | -45.57 | |||||
12-1 Month Momentum % | 12.06 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.47 | |||||
Quick Ratio | 1.23 | |||||
Cash Ratio | 0.48 | |||||
Days Inventory | 178.77 | |||||
Days Sales Outstanding | 174.43 | |||||
Days Payable | 200.4 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 2.7 | |||||
Shareholder Yield % | 9.55 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 56.3 | |||||
Operating Margin % | -35.83 | |||||
Net Margin % | -44.89 | |||||
FCF Margin % | -9.32 | |||||
ROE % | -31.94 | |||||
ROA % | -14.75 | |||||
ROIC % | -16.06 | |||||
3-Year ROIIC % | 24.81 | |||||
ROC (Joel Greenblatt) % | -219.8 | |||||
ROCE % | -17.8 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.95 | |||||
PB Ratio | 0.83 | |||||
EV-to-EBIT | -1.79 | |||||
EV-to-Forward-EBIT | -13.12 | |||||
EV-to-EBITDA | -3.2 | |||||
EV-to-Forward-EBITDA | 4.57 | |||||
EV-to-Revenue | 0.72 | |||||
EV-to-Forward-Revenue | 0.67 | |||||
EV-to-FCF | -7.84 | |||||
Price-to-Projected-FCF | 3.05 | |||||
Price-to-Median-PS-Value | 0.51 | |||||
Earnings Yield (Greenblatt) % | -55.79 | |||||
FCF Yield % | -9.28 | |||||
Forward Rate of Return (Yacktman) % | -40.87 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Mayne Pharma Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil A$) | 388.151 | ||
EPS (TTM) (A$) | -2.12 | ||
Beta | 1.48 | ||
Volatility % | 70.5 | ||
14-Day RSI | 50.17 | ||
14-Day ATR (A$) | 0.211551 | ||
20-Day SMA (A$) | 4.7745 | ||
12-1 Month Momentum % | 12.06 | ||
52-Week Range (A$) | 2.75 - 7.46 | ||
Shares Outstanding (Mil) | 85.07 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Mayne Pharma Group Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Mayne Pharma Group Ltd Stock Events
Event | Date | Price(A$) | ||
---|---|---|---|---|
No Event Data |
Mayne Pharma Group Ltd Frequently Asked Questions
What is Mayne Pharma Group Ltd(ASX:MYX)'s stock price today?
When is next earnings date of Mayne Pharma Group Ltd(ASX:MYX)?
Does Mayne Pharma Group Ltd(ASX:MYX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |